Consegna has sold its Linguet technology to Imugene; Intellipharmaceutics settles patent litigation with AstraZeneca;

> Consegna has sold its Linguet technology to Imugene in exchange for a 29% shareholding. Article

> Intellipharmaceutics has settled all outstanding patent litigation with AstraZeneca ($AZN) over the generic version of AZ's Seroquel XR, an extended-release formulation of quetiapine. Press release

> The FDA has accepted NuPathe's ($PATH) resubmission of Zelrix, its migraine patch; the target date for the FDA to complete its review of the NDA is Jan. 17. Press release

> BioAlliance Pharma has received a U.S. patent for Sitavig, a tablet that sticks to the upper gum and delivers acyclovir to treat recurrent cold sores (labial herpes). Article

> Laser-engineered dissolving microneedles could deliver nadroparin. Abstract

> BD Medical's new needle aims to improve performance and patient comfort. Press release

> Bio-Path has started enrollment of a fourth cohort of a Phase I trial of liposomal Grb-2 for leukemia. Press release

> Diabetology to develop oral insulin for India. Press release

And Finally… Alexza's ($ALXA) CEO has high expectations of receiving FDA approval for Adasuve, its inhaled antipsychotic. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.